Global Launch of RTS Carbetocin Ferring at KLE-JNMC, Belagavi on Friday

BM Bureau, July 22 : Excessive bleeding after delivery (postpartum haemorrhage, PPH) is the most common cause for death of mothers. Globally, around 35% of all maternal deaths (about 70,000)  are associated with PPH. Oxytocin is the standard medication for the prevention of postpartum haemorrhage, but it requires storage and transportation in refrigerators, which is difficult to achieve in settings like India.

A large multi-country CHAMPION trial was conducted in 10 countries (Argentina, Egypt, India, Kenya, Nigeria, South Africa, Singapore, Thailand, Uganda, United Kingdom), across 24 Hospitals; between July 7, 2015 and January 30, 2018 to compare a novel formulation of room temperature stable (RTS) carbetocin with oxytocin. A total of 29,645 women were randomized in the trial. JNMC Women’s and Children’s Health Research Unit lead site for the six Indian Hospitals including the KLES Dr Prabhakar Kore Hospital, Belagavi.

The global launch of RTS Carbetocin has been organised by JNMC Women’s and Children’s Health Research Unit in KLE Centenary Convention Center, JNMC Campus on Friday, July 23 at 10.30 am. The first dose of this injection will be given in KLES Dr Prabhakar Kore Charitable Hospital on this day. This function  will be presided by Dr Prabhakar Kore, Chairman, KLE Society and Honourable Chancellor, KLE Academy of Higher Education and Research, Belagavi n presence of eminent personalities and noted medical personalities.

Your City. Your News. On WhatsApp.

Get breaking news, local alerts, and viral updates from Belagavi – straight to your WhatsApp, before anyone else.

Join Free

POPULAR NEWS

Welcome Back!

Login to your account below

Create New Account!

Fill the forms below to register

Retrieve your password

Please enter your username or email address to reset your password.

You cannot copy content of this page